Background:
Patients with nonalcoholic steatohepatitis (NASH) cirrhosis have excellent postliver transplant survival despite having many comorbidities. We hypothesized that this could be due to a selection bias.
Methods:
We analyzed the United Network for Organ Sharing data from 2002 to 2016 and compared postliver transplant survival of NASH (n = 7935) patients with cryptogenic cirrhosis (CC) (n = 6087), alcoholic cirrhosis (AC) (n = 16 810), and autoimmune hepatitis cirrhosis (AIH) (n = 2734).
Results:
By 3 years of listing, the cumulative incidence (CI) of death or deterioration was 29% for NASH, 28% for CC and AC, and 24% for AIH, but when adjusted for risk factors, the CI was similar for NASH and AIH. The factors that increased the risk of waiting list removal due to death/deterioration were poor performance status, encephalopathy, diabetes, high Model for End-stage Liver Disease, Hispanic race, older age and a low serum albumin. Most patients were transplanted within the first year (median, 2 months; interquartile range, 1-7 months) of listing and by 5 years, the unadjusted CI of transplantation was 54% for NASH, 52% for CC, 51% for AIH, and 48% for AC. The adjusted CI of transplantation within 2 months of listing was higher for AC (subhazard ratio [SHR], 1.17), AIH (SHR, 1.17), and CC (SHR, 1.13) when compared with NASH, but after 2 months, adjusted transplantation rates decreased in AC (SHR, 0.6), AIH (SHR, 0.78), and CC (SHR, 0.95). The negative predictors of receiving a transplant were dialysis, female sex, nonwhite race, high albumin, and creatinine.
Conclusions:
Patients with NASH cirrhosis are not disadvantaged by higher waitlist removal or lower transplantation rates.
Citing Articles
The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies.
Tapper E, Fleming C, Rendon A, Fernandes J, Johansen P, Augusto M
Gastro Hep Adv. 2024; 1(6):1049-1087.
PMID: 39131247
PMC: 11307414.
DOI: 10.1016/j.gastha.2022.06.016.
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients.
Argenziano M, Kim M, Montori M, Di Bucchianico A, Balducci D, Ahn S
Hepatol Int. 2024; 18(Suppl 2):922-940.
PMID: 39012579
DOI: 10.1007/s12072-024-10692-4.
The Spillover Effects of Extending Liver Transplantation to Patients with Colorectal Liver Metastases: A Discrete Event Simulation Analysis.
Sjule H, Vinter C, Dueland S, Line P, Burger E, Bjornelv G
Med Decis Making. 2024; 44(5):529-542.
PMID: 38828508
PMC: 11283734.
DOI: 10.1177/0272989X241249154.
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management.
Battistella S, DArcangelo F, Grasso M, Zanetto A, Gambato M, Germani G
Clin Mol Hepatol. 2022; 29(Suppl):S286-S301.
PMID: 36577425
PMC: 10029965.
DOI: 10.3350/cmh.2022.0392.
Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis.
Javanbakht M, Fishman J, Moloney E, Rydqvist P, Ansaripour A
Pharmacoecon Open. 2022; 7(1):93-110.
PMID: 36104546
PMC: 9929016.
DOI: 10.1007/s41669-022-00370-2.
The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
Witkowski M, Moreno S, Fernandes J, Johansen P, Augusto M, Nair S
Pharmacoeconomics. 2022; 40(8):751-776.
PMID: 35789987
PMC: 9300564.
DOI: 10.1007/s40273-022-01140-y.
Living donor liver transplantation versus donation after brain death and donation after circulatory death liver transplantation in the US.
Black M, Gupta A, Asrani S, Ma T, Testa G, Wall A
Proc (Bayl Univ Med Cent). 2022; 35(3):273-277.
PMID: 35518809
PMC: 9037473.
DOI: 10.1080/08998280.2022.2034202.
Sitagliptin Is More Effective Than Gliclazide in Preventing Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease.
Ren J, Wang X, Yee C, Gorrell M, McLennan S, Twigg S
Molecules. 2022; 27(3).
PMID: 35163991
PMC: 8838637.
DOI: 10.3390/molecules27030727.
Natural history of NASH.
Armandi A, Bugianesi E
Liver Int. 2021; 41 Suppl 1:78-82.
PMID: 34155792
PMC: 8361694.
DOI: 10.1111/liv.14910.
NAFLD and liver transplantation: Disease burden, current management and future challenges.
Burra P, Becchetti C, Germani G
JHEP Rep. 2020; 2(6):100192.
PMID: 33163950
PMC: 7607500.
DOI: 10.1016/j.jhepr.2020.100192.
Functional Status at Liver Transplant Waitlisting Correlates With Greater Odds of Encephalopathy, Ascites, and Spontaneous Bacterial Peritonitis.
McCabe P, Hirode G, Wong R
J Clin Exp Hepatol. 2020; 10(5):413-420.
PMID: 33029049
PMC: 7527846.
DOI: 10.1016/j.jceh.2020.04.015.
Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge.
Steggerda J, Mahendraraj K, Todo T, Noureddin M
World J Gastroenterol. 2020; 26(28):4018-4035.
PMID: 32821068
PMC: 7403794.
DOI: 10.3748/wjg.v26.i28.4018.
Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.
Maliakkal B
Transl Gastroenterol Hepatol. 2020; 5:36.
PMID: 32632387
PMC: 7063524.
DOI: 10.21037/tgh.2019.12.02.
Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates .
Samji N, Heda R, Satapathy S
Transl Gastroenterol Hepatol. 2020; 5:10.
PMID: 32190778
PMC: 7061181.
DOI: 10.21037/tgh.2019.09.09.
Mortality on the UNOS Waitlist for Patients with Autoimmune Liver Disease.
Suri J, Danford C, Patwardhan V, Bonder A
J Clin Med. 2020; 9(2).
PMID: 31979326
PMC: 7074547.
DOI: 10.3390/jcm9020319.
Patients with Alcoholic Liver Disease Have Worse Functional Status at Time of Liver Transplant Registration and Greater Waitlist and Post-transplant Mortality Which Is Compounded by Older Age.
McCabe P, Galoosian A, Wong R
Dig Dis Sci. 2019; 65(5):1501-1511.
PMID: 31642005
DOI: 10.1007/s10620-019-05891-1.